MedTrace Logo

Carbetocin in the Prevention of Primary Postpartum Haemorrhage

NCT06159959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2023-12-07

No results posted yet for this study

Summary

Postpartum haemorrhage (PPH) ranks as the first cause of maternal mortality in developing countries and it is the cause of 25% of maternal deaths worldwide.

Carbetocin is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties. Like oxytocin, carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions and increased uterine tone.

Conditions

  • Post Partum Hemorrhage

Interventions

DRUG

Carbetocin

To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.

Sponsors & Collaborators

  • Ministry of Health and Population, Egypt

    lead OTHER_GOV

Principal Investigators

  • Abdallah Y Elkateb, Professor · Cairo University

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-10-01
Completion
2023-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159959 on ClinicalTrials.gov